ライフサイエンスコーパス: transforming growth factor beta1

1 so had less re-expression of fetal genes and transforming growth factor beta1.

2 portant platelet released cytokines, such as transforming growth factor beta1.

3 talloproteinase-2, alkaline phosphatase, and transforming growth factor beta1.

4 , including bone morphogenetic protein 2 and transforming growth factor beta1.

5 and blunting of profibrogenic activities of transforming growth factor beta1.

6 al and cellular events and the activation of transforming growth factor beta1.

7 egulation of profibrotic pathway mediated by transforming growth factor-beta1.

8 of fibroblasts to the stimulatory effect of transforming growth factor-beta1.

9 n-T-helper type 1-related signals, including transforming growth factor-beta1.

10 ed upregulation of CSF-1R expression via the transforming growth factor-beta1.

11 tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta1.

12 roduction of both cytokines was inhibited by transforming growth factor-beta1.

13 beta6 integrin, an activator of latent local transforming growth factor-beta1.

14 roteinase-2, matrix metalloproteinase-9, and transforming growth factor-beta1/2 and the number of Mac

15 Alu RNA expression is also induced by transforming growth factor-beta1, a major driver of EMT.

16 on memory B cells, whereas interleukin-4 and transforming growth factor-beta1 act as negative regulat

17 haVbeta6 integrin, an important regulator of transforming growth factor-beta1 activation.

18 signaling pathway, resulting in decreased LV transforming growth factor-beta1 activity (P=0.03).

19 s ability to block myostatin, activin A, and transforming growth factor-beta1, all of which are negat

20 le to undergo EMT in vitro when treated with transforming growth factor-beta1 alone or in combination

21 th factor receptor 1, 2, and 3; osteopontin; transforming growth factor beta1 and beta2; thrombospond

22 The balance between transforming growth factor beta1 and bone morphogenetic

23 nts with SCD and isolated cytokines, such as transforming growth factor beta1 and endothelin-1, enhan

24 s in CCD-18Co fibroblasts in the presence of transforming growth factor beta1 and insulin-like growth

25 llagen, vimentin, and the fibrogenic factors transforming growth factor beta1 and insulin-like growth

26 d collagen I; this was inhibited by blocking transforming growth factor beta1 and p38 mitogen-activat

27 ed products, and decreased after blockade of transforming growth factor beta1 and p38 mitogen-activat

28 es the release of active MMP2 in response to transforming growth factor beta1 and rescues tissue inte

29 Furthermore, the increase in transforming growth factor beta1 and type I transforming

30 ced expression of the profibrotic mediators, transforming growth factor-beta1 and connective tissue g

31 brosis, as well as its interaction with both transforming growth factor-beta1 and decorin.

32 L-6, but not IL-8, induced the expression of transforming growth factor-beta1 and elastic fiber prote

33 le and the numbers of which are regulated by transforming growth factor-beta1 and hypoxia.

34 was up-regulated by the profibrotic cytokine transforming growth factor-beta1 and in PD effluent-deri

35 Among the cytokines tested, transforming growth factor-beta1 and interleukin-1beta e

36 In wild-type mice, we found that transforming growth factor-beta1 and myostatin co-locali

37 Decorin prevented the increase in transforming growth factor-beta1 and phosphorylated Smad

38 d investigated the interrelationship between transforming growth factor-beta1 and secreted frizzled-r

39 any types of carcinoma where it may activate transforming growth factor-beta1 and transforming growth

40 necrosis factor-alpha and reduced levels of transforming growth factor-beta1 and vascular endothelia

41 o enhanced (by 20% to 40%) the expression of transforming growth factors beta1 and beta2, vascular en

42 renal and glomerular hypertrophy as well as transforming growth factor-beta1) and extracellular matr

43 whereas SNAI2, vimentin, S100A4, FN1, HRAS, transforming growth factor beta1, and CD44H were high.

44 talloproteinase-9, B-cell activating factor, transforming growth factor-beta1, and elastase were high

45 cytokines IL-1beta, IL-18, interferon-gamma, transforming growth factor-beta1, and IL-4 as well as hi

46 ession levels of fibroblast growth factor-2, transforming growth factor-beta1, and platelet-derived g

47 ponse to myelin perturbations, we identified transforming growth factor-beta1 as a partial mediator o

48 gnaling pathways, including Snail, Twist and transforming growth factor-beta1 as well as the mesenchy

49 ated by tissue stiffness and the profibrotic transforming growth factor-beta1, but its role in cell f

50 pression was modulated by gut microbiota and transforming growth factor-beta1, but not by retinoic ac

51 Transforming growth factor-beta1, but not endoplasmic re

52 tatin, growth differentiation factor 11, and transforming growth factor beta1, by cleaving extracellu

53 hemokine ligand 5 [CCL5]) and profibrogenic (transforming growth factor beta1, collagen type 4 alpha

54 ce, MUC5AC and matrix remodeling parameters (transforming growth factor-beta1, collagen I, and fibron

55 nd membrane-bound latency-associated peptide/transforming growth factor beta1, compared with uninfect

56 ry occlusion and were divided into 3 groups: transforming growth factor beta1-conditioned human MSC-l

57 Transforming growth factor beta1-conditioned human MSC-l

58 al expression of fibrogenic genes, including transforming growth factor beta1, connective tissue grow

59 vels of key mediators of fibrosis, including transforming growth factor beta1, connective tissue grow

60 HA-binding protein TSG-6 in maintaining the transforming growth factor beta1-dependent HA coat, TSG-

61 it as a key difference between IL-1beta- and transforming growth factor beta1-dependent HA matrices.

62 sequencing (RNA-seq) analysis revealed that transforming growth factor beta1 (encoded by Tgfb1) is e

63 tu by antagonizing E-cadherin, combined with transforming growth factor-beta1, epidermal growth facto

64 On the molecular level, microglial transforming growth factor-beta1 expression is down-regu

65 hickening, podocyte foot-process fusion, and transforming growth factor-beta1 expression were amelior

66 , pancreatic duodenal homeobox-1, and active transforming growth factor-beta1 expression were increas

67 so resulted in fibrosis, which was linked to transforming growth factor-beta1 expression.

68 Here, we show that the expression of the transforming growth factor beta1 gene (Tgfb1) affects th

69 association with CAA of polymorphisms in the transforming growth factor beta1 gene (two studies, 449

70 tides such as alpha-smooth muscle actin, and transforming growth factor-beta1 had no effect on FGFR1O

71 LGs had higher Th-17- (interleukin [IL]-23R, transforming growth factor-beta1, IL-17A, CC chemokine a

72 We determined that genetic deficiency in transforming growth factor beta1 impairs endometriosis-l

73 TGF-beta1 (transforming growth factor-beta1) importantly contribute

74 ntly reduced thrombin activity and levels of transforming growth factor beta1 in BAL fluid, while sim

75 D25(+) T regulatory cells, and production of transforming growth factor beta1 in the spleen.

76 ced marked accumulation of activin A but not transforming growth factor-beta1 in conditioned media.

77 Transforming growth factor-beta1 in PICF and GCF exhibit

78 l population and increased the expression of transforming growth factor-beta1 in the liver.

79 Extracellular TG2 was sufficient to activate transforming growth factor-beta1 in tubular epithelial c

80 es indicate that the upregulation of Nox4 by transforming growth factor-beta1 in ZO SMCs is responsib

81 The myokine transforming growth factor-beta1 increases during inflam

82 ombination of fibroblast growth factor 2 and transforming growth factor beta1 induce profound morphol

83 In isolated adult mouse cardiac fibroblasts, transforming growth factor-beta1 induced cardiac fibrobl

84 owever, activation of AhR in the presence of transforming growth factor-beta1 induced Foxp3(+) iT(reg

85 Furthermore, tumor necrosis factor-alpha and transforming growth factor-beta1 induced the expression

86 Overexpression of Epac1 inhibits transforming growth factor beta1-induced collagen synthe

87 ty of this technology to prevent and inhibit transforming growth factor beta1-induced myodifferentiat

88 ecreted frizzled-related protein 2 prevented transforming growth factor-beta1-induced atrophy in C2C1

89 Berberine reversed transforming growth factor-beta1-induced EMT and caused

90 ansplant model, and in the in vitro model of transforming growth factor-beta1-induced EMT in normal r

91 , Nox-2, phospho-smad2, and alpha-SMA during transforming growth factor-beta1-induced EMT of NRK52E c

92 ound that the miR-200 family members inhibit transforming growth factor-beta1-induced epithelial-mese

93 PAR-1 activation enhanced transforming growth factor-beta1-induced integrin beta6

94 synthetic and contractile phenotype, in both transforming growth factor-beta1-induced myofibroblast d

95 fibrosis and cardiac dysfunction by blocking transforming growth factor-beta1-induced phospho-Smad2/3

96 Previous studies have shown that transforming growth factor-beta1-induced transcript 1 (T

97 These phenomena depend on transforming growth factor-beta1 induction.

98 type with patches of collagen deposition and transforming growth factor-beta1 induction.

99 We observed that the transforming growth factor-beta1 inhibitor, secreted fri

100 nclusion of Rho-associated kinase (ROCK) and transforming growth factor-beta1 inhibitors.

101 or 1 (VEGFR1), VEGFR2, Tie2, erythropoietin, transforming growth factor beta1, insulinlike growth fac

102 We show that transforming growth factor-beta1 is responsible for the

103 Vaginal pH and the transforming growth factor beta1 level increased, but hu

104 nfiltration, proinflammatory mRNAs, and TGF-(Transforming Growth Factor-)beta1 levels.

105 nsverse aortic constriction increased active transforming growth factor-beta1 levels and phosphorylat

106 Serum transforming growth factor-beta1 levels were significant

107 if) ligand 1; stromal cell-derived factor 1; transforming growth factor-beta1; matrix metallopeptidas

108 Additionally, our data suggest that transforming growth factor-beta1 may be a factor in indu

109 Id2 also blocks transforming growth factor beta1-mediated expression of

110 tablishes a positive feedback loop enhancing transforming growth factor-beta1-mediated atrophic effec

111 rizzled-related protein 2 reduction enhances transforming growth factor-beta1-mediated effects and in

112 n of a constitutively active FOXO3a overrode transforming growth factor-beta1-mediated invasive pheno

113 3), CD11b-F4/80+Gr1+ monocytes (P < 0.0001), transforming growth factor beta1 mRNA (P = 0.04), and al

114 although anti-inflammatory IL-10, IL-13, and transforming growth factor beta1 mRNA levels were not co

115 d WT mice, but Col1 alpha1, Col3 alpha1, and transforming growth factor-beta1 mRNA increased much mor

116 observed in tumor necrosis factor-alpha and transforming growth factor-beta1 mRNA levels and intrace

117 ional repressors, snail and slug, induced by transforming growth factor-beta1 or extracellular matrix

118 lasminogen activator inhibitor 1 (P=0.0002), transforming growth factor beta1 (P=0.0004), tissue inhi

119 yme B (P<0.002), CD103 (P<0.005) but not for transforming growth factor-beta1 (P>0.05).

120 expression levels of fibrogenic markers (eg, transforming growth factor-beta1, platelet-derived growt

121 In activation of the transforming growth factor-beta1 precursor (pro-TGF-beta

122 ith previous reports, Extract PBS suppressed transforming growth factor-beta1 promoter activation in

123 Mechanistically, this process engages the transforming growth factor beta1 protein and Notch signa

124 ransforming growth factor-beta1 (TGF-beta1), transforming growth factor-beta1 receptor (TGF-beta1R),

125 Nrf2 suppressed the activity of a synthetic transforming growth factor-beta1-responsive CAGA-directe

126 ndogenous TLR4 ligands, results in augmented transforming growth factor-beta1 sensitivity with increa

127 hepatic macrophage aggregation, resulting in transforming growth factor beta1-signaled collagen depos

128 Gene set enrichment analysis uncovered transforming growth factor-beta1 signaling activation in

129 ates in a negative feedback mechanism on the transforming growth factor-beta1 signaling and downregul

130 eas the sik1(-/-) mice exhibited upregulated transforming growth factor-beta1 signaling and increased

131 arly- and late-stage cardiac remodeling with transforming growth factor-beta1 signaling at the center

132 odulation of activin-A, activin-B, Nodal and transforming growth factor-beta1 signaling.

133 on of the contractile phenotype of VSMCs via transforming growth factor-beta1-signaling inhibition.

134 hanistically, GSK-3beta inhibits profibrotic transforming growth factor-beta1/SMAD-3 signaling via in

135 Knockdown of YAP1 in transforming growth factor-beta1-stimulated dermal fibro

136 X5 SNP-expressing cells had higher basal and transforming growth factor-beta1-stimulated expression a

137 nd interleukin 1 receptor antagonist but not transforming growth factor beta1, suggesting that alkylg

138 ce similar phenotypes, as well as of several transforming growth factor-beta1 target genes, such as m

139 Transforming growth factor beta1 (TGF-beta) promotes ren

140 Transforming growth factor beta1 (TGF-beta), enriched in

141 models of fibrotic renal disease by opposing transforming growth factor beta1 (TGF-beta)-dependent fi

142 d that IL-17A mediates epithelial injury via transforming growth factor beta1 (TGF-beta1) and down-re

143 es of orally tolerized mice showed increased transforming growth factor beta1 (TGF-beta1) and interle

144 ves increased migration and up-regulation of transforming growth factor beta1 (TGF-beta1) and its dow

145 Transforming growth factor beta1 (TGF-beta1) and osteopo

146 kophilin-2 (PKP2) in cardiomyocytes elevates transforming growth factor beta1 (TGF-beta1) and p38 mit

147 We evaluated transforming growth factor beta1 (TGF-beta1) as a key up

148 eal injury typically involves fibrosis, with transforming growth factor beta1 (TGF-beta1) as one of i

149 We show that transforming growth factor beta1 (TGF-beta1) can induce

150 lower expression of the profibrogenic factor transforming growth factor beta1 (TGF-beta1) compared to

151 al immunosensor for the determination of the transforming growth factor beta1 (TGF-beta1) cytokine co

152 d activity of the immunosuppressive cytokine transforming growth factor beta1 (TGF-beta1) due to high

153 Understanding inhibitory mechanisms of transforming growth factor beta1 (TGF-beta1) has provide

154 Increased transforming growth factor beta1 (TGF-beta1) in mammary

155 Transforming growth factor beta1 (TGF-beta1) is a master

156 We show that transforming growth factor beta1 (TGF-beta1) is activate

157 Transforming growth factor beta1 (TGF-beta1) is not only

158 of proinflammatory mediators while restoring transforming growth factor beta1 (TGF-beta1) levels as e

159 CsA treatment and to investigate the role of transforming growth factor beta1 (TGF-beta1) on this CsA

160 rming cartilage in the presence of exogenous transforming growth factor beta1 (TGF-beta1) or with TGF

161 We demonstrate that the transforming growth factor beta1 (TGF-beta1) pathway up-

162 The generation of oxidative stress and transforming growth factor beta1 (TGF-beta1) production

163 .5 kPa) polyacrylamide gels (with or without transforming growth factor beta1 (TGF-beta1)) and low pr

164 Addition of blocking antibodies against transforming growth factor beta1 (TGF-beta1), -2, and -3

165 Here, we found that transforming growth factor beta1 (TGF-beta1), a critical

166 by serotonin, which activates expression of transforming growth factor beta1 (TGF-beta1), a powerful

167 r messenger RNA and/or protein expression of transforming growth factor beta1 (Tgf-beta1), collagen 1

168 It has been shown that pro-fibrotic transforming growth factor beta1 (TGF-beta1)-driven epit

169 A critical step in this process is transforming growth factor beta1 (TGF-beta1)-mediated tr

170 In spite of a large number of transforming growth factor beta1 (TGF-beta1)-regulated g

171 fibroblasts to myofibroblasts in response to transforming growth factor beta1 (TGF-beta1).

172 ofibroblast phenotype under the influence of transforming growth factor beta1 (TGF-beta1).

173 KRAS-variant with p16 status and blood-based transforming growth factor beta1 (TGF-beta1).

174 n hepatogenic profibrotic cells activated by transforming growth factor beta1 (TGF-beta1).

175 ponse to the differentiation-inducing factor transforming growth factor beta1 (TGF-beta1).

176 nse to infection, and enhanced expression of transforming growth factor beta1 (TGF-beta1).

177 e increase in collagen I and III expression, transforming growth factor-beta1 (TGF- beta1) expression

178 dels of DN, and mesangial cells treated with transforming growth factor-beta1 (TGF- beta1) or high gl

179 nt memory T cells (TRM cells) require active transforming growth factor-beta1 (TGF-beta) for epiderma

180 r matrix proteins and hypertrophy induced by transforming growth factor-beta1 (TGF-beta) in renal mes

181 Akt kinase activated by transforming growth factor-beta1 (TGF-beta) plays an imp

182 We report that expression levels of transforming growth factor-beta1 (TGF-beta), p53, and mi

183 Racial differences in the expression of transforming growth factor-beta1 (TGF-beta1) and caveoli

184 pression of Hmga2 enhances the activation of transforming growth factor-beta1 (TGF-beta1) and Cxcl12

185 A model system combining transforming growth factor-beta1 (TGF-beta1) and EGF was

186 ogenic; in fact, T(H)17 cells generated with transforming growth factor-beta1 (TGF-beta1) and IL-6 pr

187 s of BM CD45(+)Col(+) cells was regulated by transforming growth factor-beta1 (TGF-beta1) and liposac

188 interactions with soluble mediators such as transforming growth factor-beta1 (TGF-beta1) and mechani

189 s, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reducti

190 CAF express elevated levels of both transforming growth factor-beta1 (TGF-beta1) and stromal

191 in both animal models led to a reduction of transforming growth factor-beta1 (TGF-beta1) and TGF-bet

192 In the present study, we evaluate whether transforming growth factor-beta1 (TGF-beta1) and tumor n

193 Because the signaling of transforming growth factor-beta1 (TGF-beta1) and tumor n

194 Both a neutralizing anti-transforming growth factor-beta1 (TGF-beta1) antibody an

195 which autocrine production and activation of transforming growth factor-beta1 (TGF-beta1) are require

196 TSP-1 converts latent transforming growth factor-beta1 (TGF-beta1) complexes i

197 ed the rate of wound closure and reduced the transforming growth factor-beta1 (TGF-beta1) expression

198 ed systemic hypertension, suppressed Agt and transforming growth factor-beta1 (TGF-beta1) gene expres

199 Transforming growth factor-beta1 (TGF-beta1) has potent

200 s inhibited by increased accumulation of the transforming growth factor-beta1 (TGF-beta1) in skeletal

201 after stimulation with the profibrotic agent transforming growth factor-beta1 (TGF-beta1) in vitro.

202 ssion correlated with impaired activation of transforming growth factor-beta1 (TGF-beta1) in vivo and

203 Transforming growth factor-beta1 (TGF-beta1) induced end

204 Here we show that transforming growth factor-beta1 (TGF-beta1) induces MMP

205 Transforming growth factor-beta1 (TGF-beta1) induces NOX

206 We have previously demonstrated that transforming growth factor-beta1 (TGF-beta1) induces ple

207 se PKA increased, autoinductive signaling by transforming growth factor-beta1 (TGF-beta1) initiated a

208 We investigated beta-catenin-dependent and transforming growth factor-beta1 (TGF-beta1) interaction

209 ractile protein-expressing myofibroblasts by transforming growth factor-beta1 (TGF-beta1) is a critic

210 Transforming growth factor-beta1 (TGF-beta1) is a fundam

211 Transforming growth factor-beta1 (TGF-beta1) is a multif

212 Transforming growth factor-beta1 (TGF-beta1) is a multif

213 Transforming growth factor-beta1 (TGF-beta1) is a potent

214 cellular carcinoma cells and identified that transforming growth factor-beta1 (TGF-beta1) is induced

215 Transforming growth factor-beta1 (TGF-beta1) is released

216 a concomitant increase in total circulating transforming growth factor-beta1 (TGF-beta1) levels (P =

217 Transforming growth factor-beta1 (TGF-beta1) may stimula

218 to NK cell killing, which can be reversed by transforming growth factor-beta1 (TGF-beta1) neutralizin

219 his study addressed if the activation of the transforming growth factor-beta1 (TGF-beta1) pathway is,

220 P2 (S-phase kinase-associated protein 2) and transforming growth factor-beta1 (TGF-beta1) play import

221 Transforming growth factor-beta1 (TGF-beta1) plays essen

222 aim of our study was to evaluate the role of transforming growth factor-beta1 (TGF-beta1) polymorphis

223 Control-released transforming growth factor-beta1 (TGF-beta1) promoted th

224 Transforming growth factor-beta1 (TGF-beta1) protects ag

225 Transforming growth factor-beta1 (TGF-beta1) protein exp

226 Transforming growth factor-beta1 (TGF-beta1) regulates i

227 , fibroblast growth factor-2 (FGF-2), and/or transforming growth factor-beta1 (TGF-beta1) to adult bo

228 The induction of EMT by transforming growth factor-beta1 (TGF-beta1) was analyze

229 21, IL-1beta, IL-6, IL-17, IL-23, IL-10, and transforming growth factor-beta1 (TGF-beta1) were quanti

230 investigated the interaction between LOX and transforming growth factor-beta1 (TGF-beta1), a potent g

231 on of alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1), and matrix

232 ibrogenic phenotype through the induction of transforming growth factor-beta1 (TGF-beta1), collagen d

233 pression variations (versus normal aorta) of transforming growth factor-beta1 (TGF-beta1), connective

234 n expression of the Nrf2 pathway, as well as transforming growth factor-beta1 (TGF-beta1), fibronecti

235 astrocyte functions, we examined effects of transforming growth factor-beta1 (TGF-beta1), lipopolysa

236 We show that in the presence of transforming growth factor-beta1 (TGF-beta1), LRG1 is mi

237 Gene expression of transforming growth factor-beta1 (TGF-beta1), nuclear fa

238 lial-mesenchymal transition (EMT) induced by transforming growth factor-beta1 (TGF-beta1), papillary

239 In addition, COPD cultures released more transforming growth factor-beta1 (TGF-beta1), reflecting

240 S cells), expression of markers of fibrosis, transforming growth factor-beta1 (TGF-beta1), transformi

241 We identify two transforming growth factor-beta1 (TGF-beta1)-dependent m

242 ast growth factor (FGF-2) effectively blocks transforming growth factor-beta1 (TGF-beta1)-mediated my

243 ry stiffening with ageing is associated with transforming growth factor-beta1 (TGF-beta1)-related inc

244 ing and is largely regulated by the cytokine transforming growth factor-beta1 (TGF-beta1).

245 ey to this process is the mammalian cytokine transforming growth factor-beta1 (TGF-beta1).

246 sis and is largely regulated by the cytokine transforming growth factor-beta1 (TGF-beta1).

247 sion of bone morphogenic proteins (BMPs) and transforming growth factor-beta1 (TGF-beta1).

248 e loss induced by AbetaOs, via production of transforming growth factor-beta1 (TGF-beta1).

249 (Mmp2) and Mmp9, which could activate latent transforming growth factor-beta1 (TGF-beta1).

250 ce had impaired mitophagy and reduced active transforming growth factor-beta1 (TGF-beta1).

251 mice, and expression of calpain-1/2 and MMP2/transforming growth factor-beta1 (TGF-beta1).

252 in adipose tissue macrophages highlights the transforming growth factor beta1 (TGFB1) gene itself as

253 The transforming growth factor beta1 (TGFB1) polymorphism -5

254 Mice deficient in the gene encoding transforming growth factor-beta1 (Tgfb1(-/-) mice) acute

255 Transforming growth factor-beta1 (TGFB1) is a multifunct

256 d rs1982073, 'codon 10') in the 5' region of transforming growth factor-beta1 (TGFB1), a putative CF

257 Treatment with transforming growth factor beta1 (TGFbeta), which is imp

258 sembly/absence of intercellular contacts and transforming growth factor-beta1 (TGFbeta) exposure.

259 Transforming growth factor beta1 (TGFbeta1) and bone mor

260 The interaction between transforming growth factor beta1 (TGFbeta1) and hedgehog

261 Here, we show that transforming growth factor beta1 (TGFbeta1) and interleu

262 emical inhibitor of Notch signaling and anti-transforming growth factor beta1 (TGFbeta1) antibody.

263 r effects of human polymorphisms influencing transforming growth factor beta1 (TGFbeta1) expression,

264 inhibitor of metalloproteinase-1 (TIMP1) and transforming growth factor beta1 (TGFbeta1) in activated

265 Transforming growth factor beta1 (TGFbeta1) induced alph

266 We show that transforming growth factor beta1 (TGFbeta1) is a potent

267 Transforming growth factor beta1 (TGFbeta1) is required

268 Transforming growth factor beta1 (TGFbeta1) is the princ

269 Transforming growth factor beta1 (TGFbeta1) plays a cruc

270 that the integrin alphavbeta8 and its latent transforming growth factor beta1 (TGFbeta1) protein liga

271 High levels of transforming growth factor beta1 (TGFbeta1) were detecte

272 ide SLC4A2 expression under stimulation with transforming growth factor beta1 (TGFbeta1), a cytokine

273 ne human renal epithelial cells treated with transforming growth factor beta1 (TGFbeta1), a model of

274 gressive changes in renal mRNA expression of transforming growth factor beta1 (TGFbeta1), endothelin-

275 of bone morphogenetic protein 7 (BMP-7) and transforming growth factor beta1 (TGFbeta1)-induced huma

276 e medium on VN or collagen (CL) with 1 ng/mL transforming growth factor beta1 (TGFbeta1).

277 onor corneas with interleukin-10 (IL-10) and transforming growth factor-beta1 (TGFbeta1) altered the

278 Overexpression of transforming growth factor-beta1 (TGFbeta1) in the norma

279 The ubiquitously expressed cytokine transforming growth factor-beta1 (TGFbeta1) promotes car

280 factors (IRFs), IFN-stimulated genes (ISGs), transforming growth factor-beta1 (TGFbeta1), and several

281 and Cdc42 are the principal mediators of the transforming growth factor-beta1 (TGFbeta1)-stimulated e

282 s myofibroblast differentiation triggered by transforming growth factor-beta1 (TGFbeta1).

283 2 physically interacted and colocalized with transforming growth factor-beta1 through its cysteine-ri

284 SD-4 on SS cells also trapped transforming growth factor-beta1 to their cell surface,

285 nd latent paracrine signaling cytokines (eg, transforming growth factor-beta1) to promote maladaptive

286 ere, we show that the profibrogenic agonist, transforming growth factor beta1, transcriptionally decr

287 ditioned medium resulted in up-regulation of transforming growth factor-beta1, transforming growth fa

288 ed transcriptional profiling of kidneys from transforming growth factor-beta1 transgenic (Tg) mice, c

289 and interferon-gamma but increased IL-2 and transforming growth factor-beta1, two cytokines required

290 s had increased expression of the cytokines, transforming growth factor-beta1, vascular endothelial g

291 In addition, transforming growth factor-beta1 via Smad2 was necessary

292 egulation by endoplasmic reticulum stress or transforming growth factor-beta1, was analyzed by small

293 alpha-Smooth muscle actin and transforming growth factor beta1 were increased in both

294 ses in levels of periostin, collagen VI, and transforming growth factor beta1 were linearly correlate

295 urinary cell mRNA for granzyme B, CD103, and transforming growth factor-beta1 were measured to ascert

296 f CCL2, CCL3, interleukin (IL)-6, IL-10, and transforming growth factor-beta1 were significantly elev

297 factor-alpha, hepatocyte growth factor, and transforming growth factor-beta1 were significantly lowe

298 terferon-gamma, tumor necrosis factor-alpha, transforming growth factor-beta1) were evaluated.

299 ed mesenchymal cells secreted high levels of transforming growth factor-beta1, which down-regulates m

300 cient skin and wounds had elevated levels of transforming growth factor-beta1, which have been shown